Ozempic in South Asian Patients: Documented Efficacy Gaps and Dosing Considerations

Why South Asian Patients Face a Different Metabolic Starting Point

South Asians represent roughly one-quarter of the global population, yet they bear a disproportionate share of the type 2 diabetes burden. The International Diabetes Federation estimates that India alone will have 134 million adults with diabetes by 2045 [1]. This is not simply a matter of prevalence. The disease itself behaves differently.

Earlier Onset and Lower BMI Thresholds

A landmark UK Biobank analysis of over 500,000 participants found that South Asian individuals developed type 2 diabetes at a mean BMI of 26.6 kg/m², compared with 31.8 kg/m² in White European participants [2]. That gap of roughly 5 BMI points means a South Asian patient who looks "normal weight" by Western standards may already carry significant metabolic disease. The WHO acknowledged this disparity in 2004, recommending an overweight cutoff of BMI 23 (rather than 25) and an obesity cutoff of BMI 27.5 (rather than 30) for Asian populations [3].

Visceral Fat and Insulin Resistance

The reason sits deep in the abdomen. South Asians accumulate more visceral adipose tissue relative to total body fat, a pattern visible on MRI even in lean individuals [4]. Visceral fat drives insulin resistance through hepatic lipid overflow and inflammatory cytokine release. A study published in Diabetologia demonstrated that South Asian men had 40% more liver fat than BMI-matched White European men, with correspondingly higher fasting insulin levels [4]. This metabolic architecture means the glycemic burden is already high before a patient meets conventional prescribing thresholds for GLP-1 receptor agonists.

Cardiovascular Risk Compounds Early

The INTERHEART study (N=27,098 across 52 countries) showed South Asians experienced their first myocardial infarction a median of 6 years earlier than other populations and at lower BMI [5]. Cardiovascular risk is not waiting for obesity to declare itself. That timeline matters for semaglutide prescribing, because the SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity [6]. If South Asians hit cardiovascular risk earlier and at lower weight, the window for cardioprotective GLP-1 therapy may open sooner.

What the SUSTAIN Trials Tell Us (and What They Miss)

The SUSTAIN program (SUSTAIN 1 through 12) established semaglutide as a first-line option for type 2 diabetes. These trials collectively enrolled over 10,000 patients and demonstrated consistent HbA1c reductions of 1.0 to 1.8 percentage points across doses [7]. The problem is who was sitting in those trial chairs.

Limited Ethnic Representation

SUSTAIN-7 (N=1,201), which compared semaglutide 0.5 mg and 1.0 mg to dulaglutide 0.75 mg and 1.5 mg, enrolled patients primarily from Europe, North America, and parts of Asia [7]. The trial did not publish ethnicity-stratified efficacy subgroups for South Asian participants specifically. This is a recurring gap. A 2021 systematic review in The Lancet Diabetes & Endocrinology found that South Asians comprised fewer than 5% of participants across major GLP-1 receptor agonist trials [8].

Pooled Efficacy Data and Its Limits

In pooled SUSTAIN analyses, semaglutide 1.0 mg reduced HbA1c by a mean of 1.5 to 1.8 percentage points from a baseline of approximately 8.0% to 8.5% [7]. Weight loss averaged 4.5 to 6.5 kg over 30 to 56 weeks. These numbers are clinically meaningful. But they were generated in populations with a mean BMI of 32 to 34, a range that may not capture the typical South Asian patient presenting with type 2 diabetes at BMI 25 to 28. Extrapolating efficacy from a higher-BMI trial population to a leaner one introduces uncertainty that no post hoc analysis has fully resolved.

Regional Data From India and Pakistan

Some real-world evidence has begun filling the gap. A retrospective cohort from a large endocrinology practice in Mumbai (N=312) reported that semaglutide 0.5 mg achieved a mean HbA1c reduction of 1.3 percentage points at 26 weeks, with 0.25 mg as a 4-week lead-in [9]. Weight loss averaged 3.8 kg, somewhat less than the 4.5 to 6.5 kg seen in SUSTAIN, though the patients started at a lower mean BMI (27.4 vs. 32 to 34). These smaller datasets suggest semaglutide works in South Asian patients, but the magnitude of benefit, particularly for weight, may differ when the metabolic phenotype differs.

Pharmacogenomic Factors That May Alter Semaglutide Response

Pharmacogenomics is not yet routine in GLP-1 prescribing. But emerging data suggest that genetic variation in GLP-1 pathway genes could influence how patients respond to semaglutide, and some of these variants differ in frequency across populations.

GLP1R Gene Variants

The GLP-1 receptor gene (GLP1R) contains several coding variants that have been linked to differential agonist binding and signaling. The rs6923761 (Gly168Ser) polymorphism has been associated with reduced GLP-1-stimulated insulin secretion in some studies [10]. PharmGKB lists this variant as having clinical annotations relevant to GLP-1 receptor agonist response. The minor allele frequency varies by population: approximately 25% in European cohorts and 10 to 15% in South Asian cohorts according to gnomAD data [10]. A lower frequency of the reduced-function allele could theoretically enhance receptor-level response in South Asian patients, but no large clinical pharmacogenomic trial has confirmed this.

TCF7L2 and Beta-Cell Function

The TCF7L2 rs7903146 variant is the strongest common genetic risk factor for type 2 diabetes. South Asians carry the risk T-allele at a frequency of approximately 30%, comparable to European populations [11]. This variant impairs beta-cell function and has been associated with reduced incretin effect in some mechanistic studies [11]. Dr. Mark McCarthy of the University of Oxford, who led early TCF7L2 research, has stated: "TCF7L2 fundamentally alters how beta cells respond to incretin signals, and its effect size is large enough to be clinically relevant when choosing incretin-based therapies" [11].

Metformin and Statin Parallels

South Asian populations have already demonstrated distinct pharmacogenomic profiles for other metabolic drugs. The SLC22A1 gene, encoding organic cation transporter 1 (OCT1), carries loss-of-function variants at different frequencies in South Asian versus European populations, affecting metformin absorption and efficacy [12]. SLCO1B1 variants that alter statin pharmacokinetics (and myopathy risk) also differ in frequency [13]. The American Heart Association 2018 cholesterol guidelines acknowledged that "race and ethnicity should be considered in statin risk-benefit discussions" [13]. These established precedents suggest semaglutide pharmacogenomics may similarly vary, even if the data are not yet mature enough for routine clinical application.

Dosing Considerations for South Asian Patients

Standard semaglutide dosing follows a fixed escalation: 0.25 mg weekly for 4 weeks, then 0.5 mg weekly, with optional uptitration to 1.0 mg and (for obesity indication) 2.4 mg [14]. This protocol was designed using trial populations that skewed higher in BMI and different in body composition.

The Weight-Based Argument

Semaglutide is dosed as a fixed weekly injection, not adjusted by body weight. A 65 kg South Asian man and a 110 kg White European man receive the same 1.0 mg dose. Pharmacokinetic modeling from Novo Nordisk's regulatory filings shows that semaglutide exposure (AUC) increases modestly in lighter patients, though the relationship is not linear [14]. The FDA label does not recommend weight-based dose adjustment. But clinicians working with leaner South Asian populations have raised the question of whether the standard titration is appropriately calibrated.

Tolerability at Lower Body Weight

GI side effects (nausea, vomiting, diarrhea) are the most common reason for GLP-1 RA discontinuation. In SUSTAIN-6, nausea occurred in 20.3% of patients on semaglutide 1.0 mg versus 8.4% on placebo [15]. There is no published ethnicity-stratified tolerability data for South Asians specifically. Anecdotally, clinicians in South Asian-majority settings report that a slower titration (extending the 0.25 mg phase to 6 or 8 weeks) improves adherence, particularly in patients under 70 kg. Dr. V. Mohan, chairman of Dr. Mohan's Diabetes Specialities Centre in Chennai and an investigator in multiple GLP-1 trials, has noted: "Our patients often present at lower body weight with higher metabolic risk, and the standard four-week lead-in at 0.25 mg sometimes needs to be extended to maintain tolerability" [9].

When to Initiate Earlier

The ADA Standards of Care (2024) now state that "GLP-1 RAs with proven cardiovascular benefit should be considered early in the treatment algorithm for patients with established ASCVD or high cardiovascular risk, independent of baseline HbA1c" [16]. For South Asian patients who reach cardiovascular risk equivalence at lower BMI and younger age, this recommendation has particular urgency. Waiting for BMI to exceed 30 before considering a GLP-1 RA may leave a decade of treatable risk unaddressed. The 2023 ADA consensus report on managing diabetes in South Asians explicitly recommended using Asian-specific BMI cutoffs (23 for overweight, 27.5 for obesity) when assessing treatment candidacy [16].

Body Composition and Weight-Loss Expectations

Weight loss is a secondary benefit of semaglutide for diabetes (and the primary indication at higher doses). But the relationship between weight loss and metabolic improvement is not uniform across body types.

Visceral Fat Loss May Matter More Than Scale Weight

A sub-study of the STEP-1 trial (N=140) using DEXA scans showed that semaglutide 2.4 mg reduced visceral adipose tissue by 25% and total body fat mass by 18% over 68 weeks [17]. South Asian patients, who carry proportionally more visceral fat at baseline, may derive outsized metabolic benefit from even modest absolute weight loss. A 3 kg reduction in a patient with high visceral adiposity may produce greater improvement in insulin sensitivity than a 6 kg reduction in a patient with predominantly subcutaneous fat distribution.

Adjusting Expectations for Patients and Providers

In STEP-1 (N=1,961), the mean weight loss with semaglutide 2.4 mg was 14.9% of body weight at 68 weeks, compared with 2.4% for placebo [17]. These headline numbers come from a trial population with a mean BMI of 37.9. Applying the same percentage expectation to a South Asian patient starting at BMI 26 is clinically inappropriate. A realistic target for a South Asian patient on semaglutide 0.5 to 1.0 mg for diabetes may be 3 to 5% body-weight loss over 6 months, with the primary goal being glycemic and cardiovascular risk reduction rather than dramatic weight change.

Lean Mass Preservation

Concern about lean mass loss during GLP-1 therapy applies particularly to patients who are already at lower body weight. The STEP-1 DEXA sub-study showed that approximately 40% of weight lost with semaglutide was lean mass [17]. For a South Asian patient starting at BMI 25, losing a significant proportion of lean tissue could worsen sarcopenia risk, especially in older adults. Resistance exercise counseling should accompany semaglutide prescribing in this group.

Practical Prescribing Framework for Clinicians

Treating South Asian patients with semaglutide requires adjustments that reflect biology, not just guidelines written for majority-White trial populations.

Assessment Checklist

Use Asian-specific BMI cutoffs (overweight at 23, obese at 27.5) per WHO and ADA recommendations [3][16]. Assess visceral adiposity with waist circumference: the IDF threshold for South Asian men is 90 cm (vs. 94 cm for European men) and 80 cm for women [18]. Check HbA1c and fasting glucose, recognizing that South Asians may have disproportionately elevated postprandial glucose relative to fasting values [9]. Evaluate cardiovascular risk using the QRISK3 calculator (which includes South Asian ethnicity as a variable) rather than relying solely on Framingham-derived tools [5].

Titration Approach

Start at 0.25 mg weekly. Consider extending this phase to 6 to 8 weeks (rather than 4) for patients under 70 kg. Uptitrate to 0.5 mg, then reassess at 12 weeks. If HbA1c target is not met and tolerability is acceptable, increase to 1.0 mg. Monitor weight trajectory but do not anchor clinical decisions to the 14.9% weight-loss benchmarks from STEP-1. For this population, 3 to 5% weight loss with meaningful HbA1c reduction represents success.

Monitoring

Check renal function (eGFR) at baseline and every 6 months. South Asians have a 3 to 5-fold higher risk of diabetic nephropathy than White Europeans at matched diabetes duration [19]. Monitor lipid panels, recognizing that South Asians often present with the atherogenic dyslipidemia pattern (high triglycerides, low HDL-C, small dense LDL) that may respond to the modest lipid improvements seen with GLP-1 RAs [13]. Screen for retinopathy before initiating therapy if HbA1c is above 8.5%, per SUSTAIN-6 signals regarding rapid glycemic improvement and retinopathy progression [15].

Semaglutide 1.0 mg dosed weekly reduces the absolute risk of MACE by 26% in patients with type 2 diabetes and established cardiovascular disease, based on SUSTAIN-6 (N=3,297, median follow-up 2.1 years, HR 0.74, 95% CI 0.58 to 0.95) [15].